Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.57% | 66.63% | 65.73% | 82.12% | 129.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.75% | 127.27% | 151.44% | 179.63% | 170.49% |
| Operating Income | -91.75% | -127.27% | -151.44% | -179.63% | -170.49% |
| Income Before Tax | -107.62% | -147.31% | -170.85% | -195.48% | -160.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.62% | -147.31% | -170.85% | -195.48% | -160.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.62% | -147.31% | -170.85% | -195.48% | -160.63% |
| EBIT | -91.75% | -127.27% | -151.44% | -179.63% | -170.49% |
| EBITDA | -469.77% | -- | -- | -- | -- |
| EPS Basic | -70.94% | -82.83% | -4.68% | 29.49% | 54.44% |
| Normalized Basic EPS | -70.93% | -82.83% | -4.68% | 29.49% | 54.44% |
| EPS Diluted | -70.94% | -82.83% | -4.68% | 29.49% | 54.46% |
| Normalized Diluted EPS | -70.93% | -82.83% | -4.68% | 29.49% | 54.44% |
| Average Basic Shares Outstanding | 22.84% | 34.24% | 67.94% | 132.65% | 308.54% |
| Average Diluted Shares Outstanding | 22.84% | 34.24% | 67.94% | 132.65% | 308.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |